Top Page
Evgen Pharma
(LSE:TCF)
Evgen Pharma (TCF) vs. S&P 500 (SPY)
Evgen Pharma Business Overview & Revenue Model
Evgen Pharma Financial Statement Overview
| Breakdown | ||||
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 396.00K | 442.00K | 0.00 | 194.00K | 0.00 | Gross Profit |
| 385.00K | 429.00K | -16.00K | 194.00K | -21.00K | EBIT |
| -3.56M | -5.07M | -3.19M | -3.20M | -3.15M | EBITDA |
| -3.55M | -4.99M | -3.15M | -3.19M | -3.15M | Net Income Common Stockholders |
| -3.14M | -4.04M | -2.73M | -2.67M | -2.71M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.00M | 5.00M | 9.03M | 11.59M | 4.13M | Total Assets |
| 3.06M | 6.17M | 9.64M | 12.42M | 4.86M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -2.00M | -5.00M | -4.51M | -5.59M | -4.13M | Total Liabilities |
| 721.00K | 833.00K | 411.00K | 607.00K | 653.00K | Stockholders Equity |
| 2.34M | 5.34M | 9.23M | 11.81M | 4.20M |
| Cash Flow | Free Cash Flow | |||
| -3.00M | -4.03M | -2.56M | -2.93M | -2.58M | Operating Cash Flow |
| -3.00M | -4.03M | -2.56M | -2.93M | -2.58M | Investing Cash Flow |
| 0.00 | 4.52M | 1.48M | -6.00M | -1.00K | Financing Cash Flow |
| 0.00 | 0.00 | 0.00 | 10.39M | 4.67M |
Evgen Pharma Technical Analysis
Evgen Pharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | £20.40B | 69.27 | 5.02% | ― | -25.07% | -64.03% | |
53 Neutral | $314.29M | ― | -66.23% | ― | 43.84% | 74.88% | |
52 Neutral | $5.15B | 3.56 | -42.52% | 2.83% | 14.56% | -0.50% | |
49 Neutral | £5.05M | ― | -88.54% | ― | -100.00% | 26.23% | |
47 Neutral | £23.52M | ― | -87.30% | ― | ― | 71.17% | |
46 Neutral | £104.20M | ― | 167.16% | ― | -100.00% | -23.91% |
Evgen Pharma Corporate Events
TheraCryf plc has announced the appointment of Edward Wardle as a Non-Executive Director, nominated by its largest shareholder, Tracarta Ltd. The company has also granted options over 289,820,870 Ordinary Shares to certain employees and Persons Discharging Managerial Responsibility, aligning management incentives with shareholder interests. This strategic move is part of TheraCryf’s efforts to focus on its neuropsychiatry assets and maximize shareholder value, particularly through the Ox-1 antagonist program. Additionally, Dr. Alastair Smith, the Non-Executive Chair, has opted to receive his board fees in shares to extend the company’s cash runway.
Spark’s Take on GB:TCF Stock
According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.
The overall stock score reflects significant financial and technical challenges facing Evgen Pharma, including declining revenues and negative cash flow. However, recent positive corporate events and strategic initiatives provide a glimmer of hope for future improvement. The stock’s current valuation remains unattractive due to ongoing losses, contributing to a cautious outlook.
To see Spark’s full report on GB:TCF stock, click here.
TheraCryf plc announced an upcoming investor webinar to discuss its plans for the Ox-1 addiction and SFX-01 glioblastoma programs, following a recent fundraising. This initiative aims to advance the Orexin-1 antagonist to clinical trial readiness, unlocking potential commercial opportunities. The webinar, hosted by Turner Pope Investments, will feature a presentation and Q&A session, providing insights into the company’s strategic direction and market opportunities.
Theracryf PLC, a UK-based company, has announced a change in its major holdings, as Oberon Investments Limited has acquired or disposed of voting rights, crossing a significant threshold on March 11, 2025. This notification, completed on March 21, 2025, indicates Oberon now holds 3.779% of the voting rights, totaling 80,475,000 shares, which may impact the company’s governance and stakeholder influence.
Theracryf PLC, a UK-based company, has announced a change in its major holdings. First Equity Limited, acting as an investment manager for Armstrong Investments Limited, has increased its voting rights in Theracryf PLC to 8.405246%, up from a previous position of 6.113760%. This acquisition of voting rights indicates a significant shift in shareholder influence, potentially impacting the company’s strategic decisions and market positioning.
TheraCryf Plc, a UK-based company, has announced a significant change in its voting rights structure. Tracarta Limited, based in the British Virgin Islands, has acquired 19.85% of TheraCryf’s voting rights, marking a notable shift from a previous position of 0%. This acquisition could impact TheraCryf’s strategic decisions and influence its market positioning.
Theracryf PLC has announced a change in its voting rights structure due to Spreadex LTD’s acquisition or disposal of voting rights and financial instruments. This notification indicates that Spreadex LTD now holds a total of 3.8998% of voting rights in Theracryf PLC, with 3.757% through direct voting rights and 0.1428% through financial instruments. This adjustment in holdings could potentially impact the company’s governance and stakeholder dynamics, reflecting a shift in shareholder influence.
TheraCryf Plc, a UK-based company, has experienced a significant change in its shareholder structure. Tracarta Limited, based in the British Virgin Islands, has acquired 18.78% of the voting rights in TheraCryf Plc, marking a notable shift from a previous position of 0%. This acquisition could potentially impact TheraCryf’s strategic decisions and influence its market position.
TheraCryf PLC, a company involved in the pharmaceutical industry, has announced a change in its voting rights structure due to an acquisition or disposal of shares. Andrew Leach has crossed a significant threshold in voting rights, now holding 3.7565% of the total voting rights as of March 11, 2025. This change has been officially notified to the issuer on March 12, 2025, potentially impacting the company’s governance and shareholder dynamics.
TheraCryf PLC, a company involved in the pharmaceutical industry, has announced a significant change in its voting rights structure. T and I Limited has acquired a 7.5131% stake in TheraCryf, as reported on March 14, 2025, following the crossing of the threshold on March 11, 2025. This acquisition may impact the company’s governance and influence future strategic decisions.
TheraCryf PLC, a company involved in the pharmaceutical industry, has reported a change in its major holdings. Simon Gibeon, based in London, has acquired a significant portion of voting rights, totaling 3.3527% of the company’s shares. This acquisition could potentially influence the company’s future decisions and strategic direction, impacting stakeholders and market dynamics.
TheraCryf PLC, a non-UK issuer, has announced a significant change in its voting rights structure due to an acquisition or disposal of voting rights by T and I Limited. The notification indicates that T and I Limited now holds 7.5131% of the voting rights in TheraCryf, marking a notable shift in shareholder influence.
TheraCryf PLC, a company involved in the pharmaceutical industry, has issued a notification regarding a significant change in its voting rights. The notification reveals that Simon Gibeon, based in London, has crossed a threshold of 3.3527% in voting rights as of March 11, 2025. This change could potentially impact the company’s governance and decision-making processes, reflecting a shift in shareholder influence.
TheraCryf PLC, a company listed on the stock exchange, has announced a change in its major holdings. Andrew Leach has acquired a significant portion of voting rights, totaling 3.7565%, as of March 11, 2025. This acquisition could influence the company’s decision-making process and potentially impact its strategic direction.
Theracryf PLC, a UK-based company, has announced a significant change in its voting rights structure due to an acquisition or disposal of voting rights by Rathbones Investment Management Ltd and Investec Wealth & Investment Limited. The notification indicates that the total voting rights held by these entities have decreased from 6.0347% to 1.1662%, suggesting a substantial reduction in their influence over the company’s decisions. This change could impact the company’s governance and strategic direction, potentially affecting stakeholders and market perceptions.
Theracryf PLC, a UK-based issuer, has reported a change in its major holdings due to an acquisition or disposal of voting rights by First Equity Limited, based in London. The notification indicates that the voting rights held by First Equity Limited have decreased from 7.300860% to 6.113760%, with a total of 130,200,000 voting rights now held in the issuer. This change reflects a shift in the company’s shareholder structure, potentially impacting its governance and strategic decision-making.
Theracryf PLC, a UK-based company, has experienced a change in the breakdown of its voting rights. Octopus Investments Limited, based in London, England, has reduced its voting rights in Theracryf from 4.3% to 1.03%, as of March 11, 2025. This change was officially notified on March 12, 2025, indicating a significant shift in shareholder influence within the company.
TheraCryf PLC, a UK-based company, has announced a change in its major holdings due to an acquisition or disposal of voting rights by James Robert Kight. The notification indicates that Kight’s voting rights have decreased from 8.09647% to 2.63427%, which may impact the company’s shareholder dynamics and influence in decision-making processes.
TheraCryf plc announced that Dr. Helen Kuhlman, the Chief Business Officer, has purchased 1,500,000 Ordinary Shares, increasing her total shareholding to 2,555,744 shares, which represents 0.5% of the company’s issued share capital. This transaction underscores confidence in the company’s strategic direction and may positively impact its market perception, given Dr. Kuhlman’s significant role in the organization.
Theracryf PLC, a UK-based company, announced a change in the breakdown of its voting rights. Octopus Investments Limited, based in London, has reduced its voting rights in Theracryf PLC from 5.12% to 4.3%, involving a total of 21,875,000 voting rights. This adjustment reflects a significant shift in shareholder influence, potentially impacting the company’s governance and strategic decisions.
TheraCryf plc has announced a successful fundraising of £4.25 million through a placing and subscription of new shares, aimed at advancing its drug development projects. The majority of the funds will be allocated to completing the pre-clinical development of their orexin-1 antagonist and preparing for the clinical trial readiness of SFX-01 for glioblastoma treatment. The fundraising extends the company’s cash runway through 2026, enabling the company to reach key inflection points and potentially unlock commercial opportunities. Additionally, Dr. Alastair Smith has been appointed as the new Non-executive Chair, and Turner Pope Investments has been named joint broker for the company.
TheraCryf plc has appointed Dr. Alastair Smith as the Non-executive Chair, following the passing of former Chair Dr. Sue Foden. Dr. Smith, a seasoned life sciences executive, brings over 20 years of experience in public company growth and strategy, notably leading Avacta Group plc to prominence. His appointment is seen as a strong endorsement of TheraCryf’s product portfolio, which includes promising assets in areas of high unmet need, such as the Orexin-1 antagonist candidate for addictive disorders. This strategic move occurs as TheraCryf prepares to advance its Orexin-1 program to clinical readiness, marking a potential significant value inflection point for the company.